TMO
Another lab, another way to grow
Thermo Fisher Scientific says its PPD Clinical Research business has opened a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, tucked inside GoCo Health Innovation City. Fancy name aside, this is basically Thermo Fisher adding more muscle to the part of the business that helps drugmakers test, measure, and make sense of what’s happening in the body.
Why investors should care
This isn’t a flashy product launch or a giant M&A splash. But it does tell you something useful: Thermo Fisher is still putting chips on the table in its outsourced drug development services business. More lab capacity, more GLP capabilities, and more geographic reach can help the company win work from pharmaceutical and biotech customers that want less hassle and more turnkey science.
The not-so-secret sauce
The company says the new site will support customers across all phases of drug development, which is a nice way of saying it wants to be useful before a drug is famous and after it’s already in the pipeline.
- More bioanalytical capacity
- More biomarker work
- A new European foothold in a hot biotech hub
Big picture: this is the kind of infrastructure news that doesn’t make headlines on TV, but it can quietly deepen Thermo Fisher’s moat and keep the services side of the business humming.